Design and synthesis of quinolinium-based derivatives targeting FtsZ for antibacterial evaluation and mechanistic study

The discovery of small molecular inhibitors targeting essential and conserved bacterial drug targets such as FtsZ protein is a promising approach to fight against multi-drug resistant bacteria. In the present study, two new series of FtsZ inhibitors based on a 1-methylquinolinium scaffold were synthesized. The inhibitors possess a variety of substituent groups including the cyclic or linear amine skeleton at the 2- and 4-position of the quinolinium ring for structure-activity relationship study. In general, the inhibitors bearing a cyclic amine substituent at the 4-position of the quinolinium ring showed better antibacterial activity (MIC down to 0.25 μg/mL) than that at the 2-position, especially against Gram-positive bacteria. Among the twenty FtsZ inhibitors examined in various assays, A3 was identified to exhibit excellent antibacterial activity against S. aureus (MIC = 0.5–1 μg/mL), S. epidermidis (MIC = 0.25 μg/mL) and E. faecium (MIC = 1–8 μg/mL). More importantly, A3 showed low hemolytic toxicity (IC5 = 64 μg/mL) and was found not readily to induce drug resistance. A3 at 2–8 μg/mL promoted the polymerization of FtsZ and interrupted the bacterial division. Furthermore, the ligand-FtsZ interaction study conducted with circular dichroism and molecular docking revealed that A3 induced secondary structure changes of FtsZ protein upon binding to the interdomain cleft of the protein. A3 is thus a potent inhibitor of FtsZ and shows potential to be used as a new antibacterial agent against drug-resistant bacteria. [Display omitted] •Rational design of novel quinolinium-based derivatives targeting FtsZ protein.•A potent quinolinium-based inhibitor of FtsZ was identified.•The modification on quinolinium ring enhances antibacterial activity.•A3 showed low hemolytic toxicity and low tendency to induce drug resistance.